Shant Parseghian, MD
Endocrinology, Diabetes & Metabolism · Stoneham, MANPI 1366476731
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $85,063 of the $97,893 with a category attached, or 86.9%. 16 manufacturers reported payments, led by Novo Nordisk at 49.6% of the total. Reporting peaked in 2022 at $27,970 and has fallen 96.8% since, to $900 in 2025. Among endocrinology, diabetes & metabolism clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 254 payments — averaging $385.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$49K
- AstraZeneca$26K
- Lilly USA, LLC$22K
- Insulet Corporation$565
- Medtronic$273
- BETA Bionics, Inc.$157
- plus $522 from 10 others
What the payments were for
- Consulting fees$2,6003%
- Speaking & faculty fees$85,06387%
- Travel & lodging$4,2884%
- Food & beverage$5,8706%
- Education$730%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 79 | $48,576 |
| AstraZeneca | 45 | $26,281 |
| Lilly USA, LLC | 82 | $21,520 |
| Insulet Corporation | 8 | $565 |
| Medtronic(2 entities) | 14 | $273 |
| BETA Bionics, Inc. | 2 | $157 |
| Amgen(2 entities) | 5 | $120 |
| Dexcom, Inc. | 5 | $107 |
| Tandem Diabetes Care, Inc. | 3 | $73 |
| Sanofi-aventis U.S. LLC | 3 | $62 |
| Johnson & Johnson | 3 | $60 |
| Madrigal Pharmaceuticals | 1 | $27 |
| Xeris Pharmaceuticals, Inc. | 1 | $21 |
| Inspire Medical Systems, Inc. | 1 | $19 |
| Senseonics, Incorporated | 1 | $17 |
| Antares Pharma, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RYBELSUS$25,919
- FARXIGA$25,710
- Ozempic$19,604
- HUMULIN$12,875
- TRULICITY$1,654
- LYUMJEV$975
- Omnipod$467
- iLet Bionic Pancreas$396
- iLet Insulin Infusion Kit Inset$132
- iLet Insulin Infusion Kit Contact Detach$132
How this compares
$97,893 in reported general payments places this provider in the 95th percentile of 360 endocrinology, diabetes & metabolism providers in Massachusetts.
See all endocrinology, diabetes & metabolism providers in Massachusetts →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 616 | $759,332 |
| TrulicityDulaglutide | 293 | $438,228 |
| MounjaroTirzepatide | 325 | $376,995 |
| JardianceEmpagliflozin | 277 | $320,562 |
| FarxigaDapagliflozin Propanediol | 268 | $257,672 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 166 | $135,454 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 36 | $83,270 |
| JanuviaSitagliptin Phosphate | 64 | $77,448 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 297 | $54,310 |
| Tresiba Flextouch U-100Insulin Degludec | 62 | $52,900 |
| Tresiba Flextouch U-200Insulin Degludec | 44 | $50,361 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 34 | $46,077 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 45 | $43,897 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 22 | $28,804 |
| Humalog Kwikpen U-100Insulin Lispro | 83 | $28,646 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $21,520 | $815,223618 claims |
| Novo NordiskOzempic, Fiasp | $48,576 | $776,872633 claims |
| AstraZenecaFarxiga | $26,281 | $257,672268 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 360 endocrinology, diabetes & metabolism providers in Massachusetts.
Other endocrinology, diabetes & metabolism in Stoneham
- Jason GagliaBoston$2.4M
- Tamer YacoubFall River$775K
- Vanita ArodaBoston$482K
- Michael RosenblattBoston$447K
- Steven RussellBoston$445K
- Nitin TrivediWorcester$403K
- Beverly BillerBoston$346K
- Christos MantzorosBoston$243K
- Peter ButlerFlorence$216K
- Augusto Caballero-RoblesBoston$150K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.